- Home
- OTLK vs ASRV Comparison
OTLK vs ASRV Comparison
Compare OTLK & ASRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ASRV
- Stock Information
- Founded
- OTLK 2010
- ASRV 1983
- Country
- OTLK United States
- ASRV United States
- Employees
- OTLK N/A
- ASRV N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ASRV Major Banks
- Sector
- OTLK Health Care
- ASRV Finance
- Exchange
- OTLK Nasdaq
- ASRV Nasdaq
- Market Cap
- OTLK 48.3M
- ASRV 48.4M
- IPO Year
- OTLK 2016
- ASRV N/A
- Fundamental
- Price
- OTLK $1.57
- ASRV $3.05
- Analyst Decision
- OTLK Strong Buy
- ASRV
- Analyst Count
- OTLK 5
- ASRV 0
- Target Price
- OTLK $9.60
- ASRV N/A
- AVG Volume (30 Days)
- OTLK 796.7K
- ASRV 30.7K
- Earning Date
- OTLK 08-13-2025
- ASRV 07-15-2025
- Dividend Yield
- OTLK N/A
- ASRV 3.97%
- EPS Growth
- OTLK N/A
- ASRV N/A
- EPS
- OTLK 0.83
- ASRV 0.22
- Revenue
- OTLK N/A
- ASRV $53,037,000.00
- Revenue This Year
- OTLK N/A
- ASRV N/A
- Revenue Next Year
- OTLK $379.84
- ASRV N/A
- P/E Ratio
- OTLK $1.91
- ASRV $14.04
- Revenue Growth
- OTLK N/A
- ASRV 16.87
- 52 Week Low
- OTLK $0.87
- ASRV $2.03
- 52 Week High
- OTLK $9.25
- ASRV $3.08
- Technical
- Relative Strength Index (RSI)
- OTLK 40.37
- ASRV 66.14
- Support Level
- OTLK $1.65
- ASRV $2.83
- Resistance Level
- OTLK $2.04
- ASRV $2.93
- Average True Range (ATR)
- OTLK 0.12
- ASRV 0.10
- MACD
- OTLK -0.03
- ASRV -0.00
- Stochastic Oscillator
- OTLK 2.13
- ASRV 100.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ASRV AmeriServ Financial Inc.
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.